TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20094818

Group type: EXPERIMENTAL
Intervention: PlasmaJet® System (PJS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional monopolar electrocautery
Number of subjects: 60
Study: 18528751

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 1010
Study: 16006029

Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) 10-80 mg/day
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Desmethylcitalopram (DCIT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Citalopram (CIT) and Desmethylcitalopram (DCIT) combined
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Citalopram (CIT)
Number of subjects: 128
Study: 12960461

Group type: EXPERIMENTAL
Intervention: Surgery and whole brain radiotherapy for single brain metastasis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiosurgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study: 11169347

Group type: EXPERIMENTAL
Intervention: Local anesthesia (lignocaine 1% injected subcutaneously)
Number of subjects: 220

Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 220
Study: 2051429

Group type: EXPERIMENTAL
Intervention: Polypropylene (Prolene)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Polydioxanone (PDS)
Number of subjects: 100
Study: 6341261

Group type: EXPERIMENTAL
Intervention: Thymostimulin (TS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 21
Study: 30938914

Group type: EXPERIMENTAL
Intervention: Cryoballoon
Number of subjects: 120

Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 120
Study: 29426035

Group type: EXPERIMENTAL
Intervention: Cognitive Anxiety Sensitivity Treatment (CAST + cognitive bias modification)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 74
Study: 27194552

Group type: EXPERIMENTAL
Intervention: Experimental follow-up schedule group (ESG, 1-3 visits first year, n=87)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional follow-up schedule group (CSG, 4 visits first year, n=93)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both groups (CSG and ESG)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Experimental follow-up schedule group (ESG)
Number of subjects: 180
Study: 24721481

Group type: EXPERIMENTAL
Intervention: 30-minute computerized brief motivational intervention (C‐BMI) plus access to free nicotine replacement therapy (NRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information-only control group plus NRT access
Number of subjects: 0
Study: 22293664

Group type: EXPERIMENTAL
Intervention: High-fidelity human simulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized interview
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified PBL (mPBL)
Number of subjects: 0
Study: 20811917

Group type: EXPERIMENTAL
Intervention: 25 μg fentanyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50 μg fentanyl
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 60
Study: 18076804

Group type: EXPERIMENTAL
Intervention: Thalidomide combined with dexamethasone (TD group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: VAD regimen (vindesine, adriamycin, and dexamethasone) (VAD group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: VAD regimen (VAD group)
Number of subjects: 39
Study: 15780701

Group type: EXPERIMENTAL
Intervention: Sertraline, 50-150 mg/day, continuous dosing throughout the menstrual cycle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline, 50-100 mg/day, intermittent dosing for 14-16 days prior to menses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sertraline, abruptly discontinued at onset of menses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, abruptly discontinued at onset of menses
Number of subjects: 0
Study: 12523875

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 120

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 120
Study: 9801961

Group type: EXPERIMENTAL
Intervention: High anxiety sensitivity individuals
Number of subjects: 396

Group type: COMPARATOR
Intervention: Low anxiety sensitivity individuals
Number of subjects: 396
Study: 7717557

Group type: EXPERIMENTAL
Intervention: Isoflurane/nitrous oxide
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl
Number of subjects: 26
Study: 1957836

Group type: EXPERIMENTAL
Intervention: Flavone acetic acid (FAA) at 5,120 and 6,144 mg/m2 as 3-hour intravenous infusions
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Flavone acetic acid (FAA) at 10,000, 12,500, 15,000, and 17,500 mg/m2 delivered in a 24-hour constant infusion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Flavone acetic acid (FAA)
Number of subjects: 17
Study: 7223659

Group type: EXPERIMENTAL
Intervention: 160 mg slow release oxprenolol, once daily for 1 month
Number of subjects: 23

Group type: COMPARATOR
Intervention: 40 mg propranolol, four times daily for 1 month
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 160 mg slow release oxprenolol, once daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: 40 mg propranolol, four times daily
Number of subjects: 23
Study: 31648138

Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavior therapy for alcohol use disorder
Number of subjects: 138
Study: 29890543

Group type: EXPERIMENTAL
Intervention: Acromegaly related PTC (APTC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal PTC
Number of subjects: 19

Group type: COMPARATOR
Intervention: Multinodular goiter (MNG)
Number of subjects: 19

Group type: COMPARATOR
Intervention: PTC without acromegaly
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: BRAF expression in APTC
Number of subjects: 19
Study: 28678307

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 70
Study: 26527251

Group type: EXPERIMENTAL
Intervention: Versapoint bipolar electrode
Number of subjects: 102

Group type: COMPARATOR
Intervention: Diode Laser
Number of subjects: 102
Study: 24161338

Group type: EXPERIMENTAL
Intervention: Elevated lipoprotein(a) levels (Lp(a))
Number of subjects: 76880

Group type: EXPERIMENTAL
Intervention: Genetic variants (rs10455872, rs3798220) and low number of KIV-2 repeats
Number of subjects: 76880

Group type: EXPERIMENTAL
Intervention: Genetic instrumental variable analysis for Lp(a)
Number of subjects: 76880

Group type: EXPERIMENTAL
Intervention: Observational analysis for Lp(a)
Number of subjects: 76880
Study: 22094298

Group type: EXPERIMENTAL
Intervention: Primary medical treatment for advanced glaucoma
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Primary surgical treatment for advanced glaucoma
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 29
Study: 19761838

Group type: EXPERIMENTAL
Intervention: Reformulated killed oral cholera vaccine (1 dose)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Reformulated killed oral cholera vaccine (2 doses)
Number of subjects: 154
Study: 17119947

Group type: EXPERIMENTAL
Intervention: HydroCoil
Number of subjects: 200

Group type: COMPARATOR
Intervention: bare platinum coils
Number of subjects: 200
Study: 15339752

Group type: EXPERIMENTAL
Intervention: Unopposed transdermal estradiol at 0.014 mg/d (n = 208)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo (n = 209)
Number of subjects: 417
Study: 11219763

Group type: EXPERIMENTAL
Intervention: Tactile foot-discriminable symbols
Number of subjects: 38
Study: 9667484

Group type: EXPERIMENTAL
Intervention: Polylactic acid (PLA) membranes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Polyglactin‐910 (PG‐910) membranes
Number of subjects: 25
Study: 8004302

Group type: EXPERIMENTAL
Intervention: Inhalation of 15 ppm NO in air
Number of subjects: 14
Study: 1968754

Group type: EXPERIMENTAL
Intervention: formoterol (12 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: terbutaline (250 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 427003

Group type: EXPERIMENTAL
Intervention: Diflunisal 250 mg twice daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Diflunisal 375 mg twice daily
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Diflunisal taken on an empty stomach
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Diflunisal taken with meals
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 11
Study: 30970128

Group type: EXPERIMENTAL
Intervention: Constipation-dominant IBS (IBS-C)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Mixed-type IBS or diarrhea-dominant IBS
Number of subjects: 115
Study: 28169285

Group type: EXPERIMENTAL
Intervention: Plecanatide 3 mg
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: Plecanatide 6 mg
Number of subjects: 1394

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1394
Study: 25833348

Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Leuprorelin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study: 23597528

Group type: EXPERIMENTAL
Intervention: Mometasone furoate monohydrate (MFM)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 94
Study: 21819564

Group type: EXPERIMENTAL
Intervention: 1-year Disease Management Programme (DMP) led by a case manager
Number of subjects: 700

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 700
Study: 19887582

Group type: EXPERIMENTAL
Intervention: Low serum cholesterol (<200 mg/dL)
Number of subjects: 5586

Group type: COMPARATOR
Intervention: High serum cholesterol (>=200 mg/dL)
Number of subjects: 5586
Study: 17950802

Group type: EXPERIMENTAL
Intervention: Rapid-assay B-type natriuretic peptide (BNP)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Troponin I
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: PAC-derived hemodynamics
Number of subjects: 141
Study: 15128632

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia + General anesthesia (EP group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia (GA group)
Number of subjects: 40
Study: 11502935

Group type: EXPERIMENTAL
Intervention: Untreated inclusion body myositis (IBM)
Number of subjects: 11
Study: 9926771

Group type: EXPERIMENTAL
Intervention: HA-coated implants that were mobile at placement
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-HA-coated implants that were mobile at placement
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: All implants (mobile or immobile) that integrated
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: HA-coated implants (mobile)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: HA-coated implants (immobile)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-HA-coated implants
Number of subjects: 81
Study: 7953212

Group type: EXPERIMENTAL
Intervention: Individual instruction
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Feedback
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Reminders
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Educational material or group education combined with feedback
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All combinations with individual instruction
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Peer review and feedback
Number of subjects: 75
Study: 2683172

Group type: EXPERIMENTAL
Intervention: Perioperative blood transfusion in stage I breast cancer patients
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Perioperative blood transfusion in stage II breast cancer patients
Number of subjects: 812
Study: 791038

Group type: EXPERIMENTAL
Intervention: ethyl linoleate agent (hELate) applied at a dose of 25 mg/kg only once after burn
Number of subjects: 60
Study: 31277797

Group type: EXPERIMENTAL
Intervention: Aflibercept every 6 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aflibercept treat-and-adjust
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study: 28829204

Group type: EXPERIMENTAL
Intervention: Adalimumab 0.8 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab and Methotrexate
Number of subjects: 0
Study: 26170421

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No inspiratory muscle training (Control)
Number of subjects: 32
Study: 22573729

Group type: EXPERIMENTAL
Intervention: Daily cigarette smokers
Number of subjects: 143

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 143

Group type: COMPARATOR
Intervention: Former smokers
Number of subjects: 143

Group type: COMPARATOR
Intervention: Nonsmokers and former smokers
Number of subjects: 143
Study: 21051423

Group type: EXPERIMENTAL
Intervention: Point 4 injection technique (Group A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 2-point injection technique (Group B)
Number of subjects: 48
Study: 19597031

Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg/d
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Fenretinide 200 mg/d
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Combination of tamoxifen and fenretinide
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 235
Study: 16570888

Group type: EXPERIMENTAL
Intervention: CellTrans blood salvage device (group A, 32 patients)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Redivac high vacuum drainage system (group B, 17 patients)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CellTrans blood salvage device (group A)
Number of subjects: 49
Study: 15617460

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Perindopril 4 mg
Number of subjects: 60
Study: 11317092

Group type: EXPERIMENTAL
Intervention: Educational program for physicians and nursing home staff
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 147
Study: 8988819

Group type: EXPERIMENTAL
Intervention: 3 micrograms.kg‐1 sufentanil
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 15 micrograms.kg‐1 sufentanil
Number of subjects: 34
Study: 8265321

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines (AC)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Whole-cell pertussis vaccines (WC)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines (AC) containing filamentous hemagglutinin (FHA)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Monocomponent PT vaccine
Number of subjects: 240
Study: 3103662

Group type: EXPERIMENTAL
Intervention: Fresh gas flow (FGF) of 70 ml kg‐1 min‐1
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fresh gas flow (FGF) of 100 ml kg‐1 min‐1
Number of subjects: 32
Study: 31348051

Group type: EXPERIMENTAL
Intervention: BUHE intubation position
Number of subjects: 138

Group type: COMPARATOR
Intervention: GLSC laryngoscopy
Number of subjects: 138
Study: 28883225

Group type: EXPERIMENTAL
Intervention: Carvedilol (2.5 mg/5 mg/20 mg)
Number of subjects: 360
Study: 27295199

Group type: EXPERIMENTAL
Intervention: High motivated performance (HMP) condition
Number of subjects: 42

Group type: COMPARATOR
Intervention: Low motivated performance (LMP) condition
Number of subjects: 42
Study: 25328464

Group type: EXPERIMENTAL
Intervention: Ceramic-on-ceramic bearing system
Number of subjects: 28
Study: 23363386

Group type: EXPERIMENTAL
Intervention: Levothyroxine administration with breakfast
Number of subjects: 45

Group type: COMPARATOR
Intervention: Levothyroxine administration while fasting
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both regimens (with breakfast and fasting)
Number of subjects: 45
Study: 19692379

Group type: EXPERIMENTAL
Intervention: Vitrectomy without ILM peeling
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Vitrectomy with 0.05% isotonic ICG‐assisted ILM peeling
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Vitrectomy with 0.15% trypan blue‐assisted ILM peeling
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 74
Study: 18418719

Group type: EXPERIMENTAL
Intervention: Thoracic electrical bioimpedance (TEB) cardiac output (CO) measured using NICOMON (Larsen & Toubro Ltd. India)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Thermodilution (Td) cardiac output (CO) measured using a PAC
Number of subjects: 35
Study: 15919144

Group type: EXPERIMENTAL
Intervention: Pure OCD participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comorbid OCD + TS participants
Number of subjects: 0
Study: 14504060

Group type: EXPERIMENTAL
Intervention: palonosetron 0.25 mg
Number of subjects: 570

Group type: COMPARATOR
Intervention: ondansetron 32 mg
Number of subjects: 570
Study: 10893654

Group type: EXPERIMENTAL
Intervention: Cizolirtine citrate (E-4018) 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cizolirtine citrate (E-4018) 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cizolirtine citrate (E-4018) 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8867253

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 55
Study: 1637761

Group type: EXPERIMENTAL
Intervention: Revealed-results group
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Withheld-results group
Number of subjects: 1000
Study: 4022214

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (600 mg daily for 30 days)
Number of subjects: 30
Study: 30585769

Group type: EXPERIMENTAL
Intervention: Predictive Low-Glucose Management (PLGM) system
Number of subjects: 8523

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8523
Study: 30285823

Group type: EXPERIMENTAL
Intervention: Web-based education program delivered by teachers at schools for Intermediate Vocational Education.
Number of subjects: 1820

Group type: COMPARATOR
Intervention: Control group (no web-based program).
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: Web-based education program.
Number of subjects: 1820
Study: 27282502

Group type: EXPERIMENTAL
Intervention: Nondepressed group
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Depressed group
Number of subjects: 430
Study: 25247929

Group type: EXPERIMENTAL
Intervention: Intravenous ferric‐carboxymaltose (2 ml, 100 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal saline (PLACEBO)
Number of subjects: 14
Study: 21878454

Group type: EXPERIMENTAL
Intervention: Sativex (nabiximols)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 20007337

Group type: EXPERIMENTAL
Intervention: Flaxseed bread (25 g of flaxseed, 46 mg lignans)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (wheat bran, <1 mg lignans)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Flaxseed bread
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 17409026

Group type: EXPERIMENTAL
Intervention: Multifactor intervention program
Number of subjects: 0
Study: 16846682

Group type: EXPERIMENTAL
Intervention: Barrier cream
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rubber gloves
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rubber gloves plus respirator
Number of subjects: 10

Group type: COMPARATOR
Intervention: No personal protective equipment
Number of subjects: 10
Study: 12792350

Group type: EXPERIMENTAL
Intervention: 300 mg of tenofovir DF once daily
Number of subjects: 189
Study: 10858988

Group type: EXPERIMENTAL
Intervention: Lyophilized A. simplex larvae (1, 5, or 25 larvae) or lyophilized antigen
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Conjunctival provocation tests
Number of subjects: 12
Study: 8856395

Group type: EXPERIMENTAL
Intervention: High protein diet (36% energy as protein)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low protein diet (15% energy as protein, high in carbohydrate)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low protein diet (15% energy as protein, high in fat)
Number of subjects: 8
Study: 1847127

Group type: EXPERIMENTAL
Intervention: Induction regimen of external beam radiotherapy to the liver (21.0 Gy, 3.0 Gy/Fx, 10 MV photons, 4 days per week) with low-dose chemotherapy (5-Fluorouracil (FU), 500 mg, i.v.; Doxorubicin, 15 mg, i.v.) on treatment Days 1, 3, 5 and 7.
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy as hyperfractionated treatment (1.2 Gy twice daily, 4 hours separation, 5 days per week, 24.0 Gy total) with similar chemotherapy.
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Induction regimen with cycles of radiolabeled antibody therapy (30 mCi I-131 antiferritin, Day 0, and 20 mCi, Day 5).
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Karnofsky Performance Score (KPS) (80-100 vs. less than 80).
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Presence/absence of ascites.
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Bilirubin level (less than 1.5 vs. greater than or equal to 1.5).
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: SGOT (less than or equal to 35 vs. greater than 35).
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase (less than or equal to 95 vs. greater than 95).
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: AFP status stratification.
Number of subjects: 216
Study: 6338063

Group type: EXPERIMENTAL
Intervention: Plasmapheresis
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham‐plasmapheresis
Number of subjects: 6
Study: 31113194

Group type: EXPERIMENTAL
Intervention: European Randomized study of Screening for Prostate Cancer calculator (ERSPC)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Prostate specific antigen (PSA)
Number of subjects: 195
Study: 28711119

Group type: EXPERIMENTAL
Intervention: Bias reduction (avoid food stimulus) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bias enhancement (attend to food stimulus) group
Number of subjects: 0